Glaxo says execs may have broken Chinese law

New York Times

The British pharmaceutical giant GlaxoSmithKline said that some of its executives might have broken the law in China, the company’s strongest statement yet on a bribery and corruption scandal that has engulfed its China operations.

Letter
to the
Editor

Send us a letter

Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

Recommended for You
U.S. Food and Drug Administration (FDA)
Upcoming FDA draft on pulse oximetry's racial bias draws questions
Most Popular
1
Sutter Health Plus taps ex-Cigna exec as CEO
2
UnitedHealthcare CEO’s killing unleashes rage against insurers
3
Digital health companies face time crunch with employer contracts
4
NYPD awaits DNA test results in UnitedHealthcare CEO's killing
5
How the new Trump administration could hurt provider finances